A poll sug­gests vac­cine da­ta boost­ed Pfiz­er's pub­lic im­age, but oth­er da­ta point to long road ahead

For much of the phar­ma­ceu­ti­cal in­dus­try, the pan­dem­ic pre­sent­ed an op­por­tu­ni­ty: to prove their val­ue to the world and turn pub­lic opin­ion around on a busi­ness much of the coun­try had come to dis­dain.

That the­o­ry — that help­ing pull the coun­try from a pan­dem­ic could neu­tral­ize years of anger over high drug prices — was put to its biggest test this month, as three dif­fer­ent drug­mak­ers an­nounced da­ta from their Covid-19 vac­cines, of­fer­ing the first ma­jor ev­i­dence that in­dus­try-built in­oc­u­la­tions could turn the tide of the out­break in the US.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.